Literature DB >> 11600391

Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.

K Nagai1, T A Davies, L M Ednie, A Bryskier, E Palavecino, M R Jacobs, P C Appelbaum.   

Abstract

Activities of HMR 3787 and RU 64399 were compared to those of three macrolides, telithromycin, and clindamycin against 175 Streptococcus pneumoniae isolates and 121 Streptococcus pyogenes isolates. HMR3787 and telithromycin were the most active compounds tested against pneumococci. Telithromycin and RU 64399 were equally active against macrolide-susceptible (MICs, 0.008 to 0.06 microg/ml) and -resistant S. pyogenes isolates, but HMR 3787 had lower MICs for ermB strains.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11600391      PMCID： PMC90817          DOI： 10.1128/AAC.45.11.3242-3245.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  Emergence of mefA and mefE genes in beta-haemolytic streptococci and pneumococci in France.

Authors:  C Arpin; M H Canron; P Noury; C Quentin
Journal:  J Antimicrob Chemother       Date:  1999-07       Impact factor: 5.790

2.  Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada.

Authors:  J C De Azavedo; R H Yeung; D J Bast; C L Duncan; S B Borgia; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

3.  Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997.

Authors:  E L Kaplan; D R Johnson; M C Del Rosario; D L Horn
Journal:  Pediatr Infect Dis J       Date:  1999-12       Impact factor: 2.129

4.  Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.

Authors:  T A Davies; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

5.  Erythromycin resistance genes in group A streptococci in Finland. The Finnish Study Group for Antimicrobial Resistance.

Authors:  J Kataja; P Huovinen; M Skurnik; H Seppälä
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

6.  Macrolide resistance in group A streptococci.

Authors:  D Savoia; C Avanzini; K Bosio; G Volpe; D Carpi; G Dotti; M Zucca
Journal:  J Antimicrob Chemother       Date:  2000-01       Impact factor: 5.790

7.  Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children: influence of macrolide resistance on clinical and microbiological outcomes. Artemis-Italy Study Group.

Authors:  P E Varaldo; E A Debbia; G Nicoletti; D Pavesio; S Ripa; G C Schito; G Tempera
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

8.  High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. Spanish Group for the Study of Infection in the Primary Health Care Setting.

Authors:  J I Alós; B Aracil; J Oteo; C Torres; J L Gómez-Garcés
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

9.  Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients.

Authors:  E Bingen; F Fitoussi; C Doit; R Cohen; A Tanna; R George; C Loukil; N Brahimi; I Le Thomas; D Deforche
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

10.  Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California.

Authors:  M K York; L Gibbs; F Perdreau-Remington; G F Brooks
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948
View more
  5 in total

1.  Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.

Authors:  Pamela R Tessier; Holly M Mattoes; Prachi K Dandekar; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.

Authors:  Glenn A Pankuch; Linda M Kelly; Gengrong Lin; Andre Bryskier; Catherine Couturier; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 3.  Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.

Authors:  Jack B Anon; Michael R Jacobs; Michael D Poole; Paul G Ambrose; Mark S Benninger; James A Hadley; William A Craig
Journal:  Otolaryngol Head Neck Surg       Date:  2004-01       Impact factor: 3.497

4.  Activities of HMR 3787 and RU 64399 compared with those of four other agents against Haemophilus influenzae and Haemophilus parainfluenzae.

Authors:  Bülent Bozdogan; Catherine Clark; Andre Bryskier; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

5.  Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Chun-Ming Lee; Wen-Kuei Huang; Tsu-Lan Wu; Jen-Hsien Wan; Dine Yang; Jainn-Ming Shyr; Yin-Ching Chuang; Jing-Jou Yan; Jang-Jih Lu; Jiunn-Jong Wu; Wen-Chien Ko; Feng-Yee Chang; Yi-Chueh Yang; Yeu-Jun Lau; Yung-Ching Liu; Hsieh-Shong Leu; Cheng-Yi Liu; Kwen-Tay Luh
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.